US2015056228A1PendingUtilityA1
Methods and materials for generating t cells
Est. expiryFeb 19, 2029(~2.6 yrs left)· nominal 20-yr term from priority
Inventors:Keith L. Knutson
C07K 7/08A61K 2039/64A61P 37/04C07K 5/101C07K 14/70539C12N 2501/998C07K 2319/33A61K 2039/6031A61K 39/385C07K 2319/01C07K 2319/50A61K 40/4205A61K 40/4202A61K 40/24A61K 40/19A61K 40/11A61K 2239/38A61K 2239/31C12N 5/0636
61
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The document provides to methods and materials for generating T cells (e.g., antigen-specific CD4 + T cells). For example, methods and materials for using nested MHC class II epitopes as vaccines to generate activated CD4 + T cells in vivo or as reagents to generate activated CD4 + T cells ex vivo are provided.
Claims
exact text as granted — not AI-modified1 - 16 . (canceled)
17 . A method for activating T cells in a mammal, said method comprising administering a composition comprising a polypeptide to said mammal, wherein said polypeptide comprises an invariant chain amino acid sequence, an MHC class II epitope amino acid sequence, and a DC3 amino acid sequence, wherein said polypeptide is between 20 and 80 amino acids in length, wherein said invariant chain amino acid sequence comprises LRMK (SEQ ID NO:44), wherein said DC3 amino acid sequence comprises FYPSYHSTPQRP (SEQ ID NO:2), and wherein said MHC class II epitope amino acid sequence is a sequence of an FRα polypeptide, a CEA polypeptide, an HER-2/neu polypeptide, or an IGFBP-2 polypeptide.Join the waitlist — get patent alerts
Track US2015056228A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.